Alkermes plc (ALKS) SEC Filings & Earnings Calls

No material risk; board appointment is routine governance.

“No departure or controversy; standard director compensation disclosed.”

No material risk signals; debt refinancing reduces interest cost

Integration risk from Avadel acquisition

“The Company incurred approximately $35.9 million of transaction costs during the six months ended June 30, 2026.”

Increased leverage

“LONG-TERM DEBT 1,476,611 ... Interest expense (46,817)”

Contingent consideration liability

“Contingent payments of up to $165.7 million may become due to former Avadel shareholders upon the achievement of the CVR Milestone.” · word for word

Contingent consideration risk from Avadel acquisition; $26.4M charge due to CVR milestone deemed more likely

“Change in fair value of contingent consideration $26.4M related to CVR milestone associated with Avadel acquisition”

GAAP net loss guidance widened; profitability pressured by acquisition-related costs

“GAAP Net Loss guidance updated to ($95)-($115)M from ($70)-($90)M”

Minimal risk; termination without penalty; no ongoing obligations

“No penalties incurred; mutual release of claims”

Pipeline dependency; alixorexton still in phase 3; regulatory approval not guaranteed

“Alixorexton is investigational; phase 3 Brilliance Studies and phase 2 Vibrance-3 study ongoing”

Potential dilution from increased authorized shares for equity compensation.

“Shareholders approved increase in authorized shares by 5.9M for equity incentive plan.”

GAAP net loss due to acquisition-related costs from Avadel acquisition.

“GAAP Net Loss of $66.5 million, compared to income of $22.5 million in prior year.” · word for word

Acquisition integration risk

“The Avadel Acquisition added significant goodwill ($513M) and intangible assets ($1.79B), with integration costs and contingent consideration.”

Leverage and debt service risk

“Long-term debt of $1.48B and interest expense of $20.9M in Q1 2026, up from $0 in prior year.”

CEO Transition Risk

“On February 24, 2026, Mr. Pops notified the Company of his decision to retire from the position of Chief Executive Officer, effective July 31, 2026.” · word for word

Equity Dilution from Share Reserve Increase

“increase the number of ordinary shares authorized for issuance thereunder by 5,900,000 new ordinary shares” · word for word

Acquisition Integration Risk

“In October 2025, we announced entry into an agreement to acquire Avadel and, in February 2026, we completed the acquisition” · word for word

Leadership transition risk is mitigated by internal promotion and continued Chairman role for outgoing CEO.

“Succession plan is orderly; Jackson has deep operational knowledge as COO.”

Revenue decline from prior year due to manufacturing & royalty revenue changes; GAAP net income decreased significantly.

“Total revenues $1,475.9M in FY2025 vs $1,557.6M in FY2024; GAAP net income $241.7M vs $367.1M.”

Generic Competition for VIVITROL

“we granted Teva a non-exclusive, royalty-free, non-transferable, non-sublicensable limited license under the remaining patent covering VIVITROL to market and sell a generic version of VIVITROL in the U.S. beginning on January 15, 2027” · word for word

High Leverage from Avadel Acquisition

“the Credit Agreement provides for (i) a senior secured term loan A facility in an aggregate principal amount of up to $750.0 million and (ii) a senior secured term loan B facility in an aggregate principal amount of up to $775.0 million” · word for word

High leverage from $1.525B debt; integration risk of Avadel; potential dilution if debt not managed.

“Credit Agreement provides for $1.525B in term loans; full amount drawn on closing.”

Preliminary results subject to audit; clinical development risks for pipeline candidates.

“Preliminary, unaudited and subject to change; clinical development activities may not be initiated or completed on expected timelines.”

Clinical and regulatory risk remains; phase 3 outcomes may differ from phase 2

“Forward-looking statements caution that initial results may not be predictive of future stages”

Increased leverage from bridge financing for acquisition

“Alkermes entered into Amended and Restated Bridge Credit Agreement; J.P. Morgan provided fully committed financing.”

Execution risk: integration of Avadel and achieving CVR milestone (FDA approval for LUMRYZ in idiopathic hypersomnia by end of 2028)

“CVR contingent upon final FDA LUMRYZ Approval for idiopathic hypersomnia in adults by end of 2028.”

Phase 3 development risk

“Phase 2 data positive but Phase 3 trials may fail.”

Proposed acquisition of Avadel Pharmaceuticals introduces integration risk.

“Our proposed acquisition of Avadel Pharmaceuticals announced last week.” · word for word

Increased R&D and SG&A spending pressure on profitability

“The decrease in net income from continuing operations of $10.0 million during the three months ended September 30, 2025, as compared to the three months ended September 30, 2024, was primarily due to an increase of $31.7 million in total expenses, primarily due to increases in research and development expenses and selling, general and administrative expenses” · word for word

Dependence on manufacturing and royalty revenue from partners

“The decrease in Other manufacturing and royalty revenue during the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024, was primarily due to a $13.6 million decrease in revenue from FAMPYRA, as our manufacturing obligations for FAMPYRA concluded on December 31, 2024.” · word for word